Marques Adriana
Laboratory of Clinical Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892, USA.
Infect Dis Clin North Am. 2008 Jun;22(2):341-60, vii-viii. doi: 10.1016/j.idc.2007.12.011.
Studies have shown that most patients diagnosed with chronic Lyme disease either have no objective evidence of previous or current infection with Borrelia burgdorferi or are patients who should be classified as having post-Lyme disease syndrome, which is defined as continuing or relapsing nonspecific symptoms (such as fatigue, musculoskeletal pain, and cognitive complaints) in a patient previously treated for Lyme disease. Despite extensive study, there is currently no clear evidence that post-Lyme disease syndrome is caused by persistent infection with B burgdorferi. Four randomized placebo-controlled studies have shown that antibiotic therapy offers no sustained benefit to patients who have post-Lyme disease syndrome. These studies also showed a substantial placebo effect and a significant risk of treatment-related adverse events. Further research to elucidate the mechanisms underlying persistent symptoms after Lyme disease and controlled trials of new approaches to the treatment and management of these patients are needed.
研究表明,大多数被诊断为慢性莱姆病的患者,要么没有先前或当前感染伯氏疏螺旋体的客观证据,要么属于应被归类为患有莱姆病后综合征的患者,莱姆病后综合征的定义是,在先前接受过莱姆病治疗的患者中持续或复发的非特异性症状(如疲劳、肌肉骨骼疼痛和认知方面的主诉)。尽管进行了广泛研究,但目前尚无明确证据表明莱姆病后综合征是由伯氏疏螺旋体的持续感染引起的。四项随机安慰剂对照研究表明,抗生素治疗对患有莱姆病后综合征的患者没有持续益处。这些研究还显示出显著的安慰剂效应以及与治疗相关的不良事件的重大风险。需要进一步研究以阐明莱姆病后持续症状的潜在机制,并对这些患者的治疗和管理新方法进行对照试验。